Our growth story

Since its inception in 2014, specialist clinical Contract Research Organisation, Aptus Clinical has grown from strength to strength. Having won BioNow’s Start-up of the year in 2016 and been a shortlisted finalist for OBN’s Specialist CRO of the Year in…

Read more >
March 22 2019 0 comments

Why are we based at Alderley Park?

Alderley Park has been the home of scientific innovation for decades, particularly for oncology research. Here a number of contributors, including our CEO Steve McConchie, explain the advantages of building a business here.

Read more >
March 19 2019 0 comments

After the ‘Meaningful Vote’, MHRA guidance in event of a no-deal Brexit scenario

Following the ‘Meaningful Vote’ on the 15th of January, in which MPs voted down the Prime Minister Theresa May’s Brexit Deal, Aptus Clinical would like to reiterate the updated guidance from the MHRA in the event of a no deal…

Read more >
January 16 2019 0 comments

Aptus Clinical receive £150k from NPIF-FW Capital Debt Finance

Aptus Clinical, a specialist clinical contract research organisation based at Alderley Park, has received a £150k loan from the Northern Powerhouse Investment Fund (NPIF) – FW Capital Debt Finance, managed by FW Capital and part of the NPIF. The growth…

Read more >
October 30 2018 0 comments

Cell & Gene Therapy Catapult Partnership

APTUS CLINICAL AND THE CELL AND GENE THERAPY CATAPULT ANNOUNCE THEIR CLINICAL SERVICE PARTNERSHIP TO SUPPORT ADVANCED THERAPY DEVELOPMENT IN THE UK Following a rigorous selection process Aptus Clinical have been appointed as a supplier for Clinical Services by the…

Read more >
October 3 2018 0 comments
October 1 2018 0 comments

Great to see our friends at Blueberry Therapeutics achieve this

Read more >
August 20 2018 0 comments

Aptus Clinical delighted by MHRA announcement on CTR

MHRA update on Clinical Trials Regulation Aptus Clinical are delighted at the MHRAs announcement this week that the UK will follow the EU Clinical Trials Regulation (CTR) when it is implemented in 2020. This provides much needed reassurance for us…

Read more >
August 8 2018 0 comments

Aptus Clinical enters into a global partnership agreement with Artelo Biosciences

Press Release Artelo Biosciences ENTERS INTO GLOBAL R&D PARTNERSHIP WITH SYNGENE INTERNATIONAL and APTUS CLINICAL for the clinical development of ART27.13 in oncology LA JOLLA, CA – June 5, 2018 – Artelo Biosciences, Inc. (OTCQB: ARTL), a biopharmaceutical company focused…

Read more >
June 12 2018 0 comments

CEO gives a talk at the Advanced Therapies & Regenerative Medicine Congress

Aptus Clinical CEO Steve McConchie discusses Aptus Clinical and their role in iMATCH at the World Advanced Therapies & Regenerative Medicine Congress May 2018.

Read more >
June 6 2018 0 comments